Invenomic Capital Management LP Boosts Stock Holdings in Concentrix Corporation $CNXC

Invenomic Capital Management LP boosted its stake in shares of Concentrix Corporation (NASDAQ:CNXC) by 19.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 822,345 shares of the company’s stock after buying an additional 135,429 shares during the quarter. Concentrix makes up 1.8% of Invenomic Capital Management LP’s portfolio, making the stock its 9th largest position. Invenomic Capital Management LP owned 1.32% of Concentrix worth $37,951,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in CNXC. Royal Bank of Canada increased its position in shares of Concentrix by 9.5% during the first quarter. Royal Bank of Canada now owns 47,501 shares of the company’s stock worth $2,643,000 after acquiring an additional 4,133 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Concentrix by 75.1% in the first quarter. Goldman Sachs Group Inc. now owns 423,287 shares of the company’s stock valued at $23,552,000 after purchasing an additional 181,546 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Concentrix by 17.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 146,515 shares of the company’s stock worth $8,152,000 after purchasing an additional 21,746 shares in the last quarter. Focus Partners Wealth purchased a new position in Concentrix during the 1st quarter worth $781,000. Finally, Geneos Wealth Management Inc. increased its holdings in Concentrix by 532.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 620 shares of the company’s stock worth $34,000 after purchasing an additional 522 shares during the period. 90.34% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Christopher A. Caldwell bought 1,000 shares of the stock in a transaction on Thursday, January 29th. The stock was bought at an average cost of $37.07 per share, for a total transaction of $37,070.00. Following the completion of the purchase, the chief executive officer directly owned 362,075 shares in the company, valued at approximately $13,422,120.25. The trade was a 0.28% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.90% of the stock is currently owned by company insiders.

Concentrix Price Performance

CNXC opened at $31.67 on Monday. The firm has a market capitalization of $1.94 billion, a PE ratio of -1.52, a price-to-earnings-growth ratio of 0.33 and a beta of 0.50. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.40 and a quick ratio of 1.40. The business’s 50-day moving average is $36.91 and its two-hundred day moving average is $41.37. Concentrix Corporation has a 1 year low of $29.35 and a 1 year high of $66.00.

Concentrix (NASDAQ:CNXC) last released its quarterly earnings results on Tuesday, January 13th. The company reported $2.95 EPS for the quarter, beating the consensus estimate of $2.93 by $0.02. Concentrix had a negative net margin of 13.02% and a positive return on equity of 16.91%. The business had revenue of $2.55 billion during the quarter, compared to analyst estimates of $2.54 billion. During the same period in the prior year, the firm posted $3.26 earnings per share. The company’s quarterly revenue was up 4.3% on a year-over-year basis. Concentrix has set its Q1 2026 guidance at 2.570-2.690 EPS and its FY 2026 guidance at 11.480-12.070 EPS. Research analysts anticipate that Concentrix Corporation will post 10.11 earnings per share for the current fiscal year.

Concentrix Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, February 10th. Investors of record on Friday, January 30th were given a dividend of $0.36 per share. The ex-dividend date of this dividend was Friday, January 30th. This represents a $1.44 dividend on an annualized basis and a yield of 4.5%. Concentrix’s dividend payout ratio is presently -6.91%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on CNXC shares. Barrington Research reiterated an “outperform” rating and issued a $62.00 target price on shares of Concentrix in a report on Monday, January 12th. Weiss Ratings cut shares of Concentrix from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, January 29th. Wall Street Zen upgraded shares of Concentrix from a “hold” rating to a “buy” rating in a report on Saturday, February 14th. Finally, Robert W. Baird set a $52.00 price target on shares of Concentrix in a research report on Wednesday, January 14th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $63.75.

Concentrix Profile

Concentrix Inc (NASDAQ: CNXC) is a global business services company specializing in customer engagement solutions and technology‐driven business process outsourcing. The firm’s offerings encompass customer care delivered across voice and digital channels, back‐office processing, analytics and consulting, and automated workflow management. By integrating proprietary platforms, strategic partnerships and advanced automation, Concentrix helps clients enhance customer experiences and streamline operations.

Its capabilities extend to digital marketing and technology implementation, leveraging artificial intelligence, machine learning and data analytics to optimize customer journeys.